These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38853036)

  • 21. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
    O'Brien KL; Chandran A; Weatherholtz R; Jafri HS; Griffin MP; Bellamy T; Millar EV; Jensen KM; Harris BS; Reid R; Moulton LH; Losonsky GA; Karron RA; Santosham M;
    Lancet Infect Dis; 2015 Dec; 15(12):1398-408. PubMed ID: 26511956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants.
    Madhi SA; Polack FP; Piedra PA; Munoz FM; Trenholme AA; Simões EAF; Swamy GK; Agrawal S; Ahmed K; August A; Baqui AH; Calvert A; Chen J; Cho I; Cotton MF; Cutland CL; Englund JA; Fix A; Gonik B; Hammitt L; Heath PT; de Jesus JN; Jones CE; Khalil A; Kimberlin DW; Libster R; Llapur CJ; Lucero M; Pérez Marc G; Marshall HS; Masenya MS; Martinón-Torres F; Meece JK; Nolan TM; Osman A; Perrett KP; Plested JS; Richmond PC; Snape MD; Shakib JH; Shinde V; Stoney T; Thomas DN; Tita AT; Varner MW; Vatish M; Vrbicky K; Wen J; Zaman K; Zar HJ; Glenn GM; Fries LF;
    N Engl J Med; 2020 Jul; 383(5):426-439. PubMed ID: 32726529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.
    Schmoele-Thoma B; Zareba AM; Jiang Q; Maddur MS; Danaf R; Mann A; Eze K; Fok-Seang J; Kabir G; Catchpole A; Scott DA; Gurtman AC; Jansen KU; Gruber WC; Dormitzer PR; Swanson KA
    N Engl J Med; 2022 Jun; 386(25):2377-2386. PubMed ID: 35731653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longer interval between maternal RSV vaccination and birth increases placental transfer efficiency.
    Jasset MOJ; Andrea Lopez Zapana P; Bahadir Z; Shook L; Dennis MM; Gilbert ME; Liu MZA; Yinger MRV; Bald MC; Bradford MCG; Silfen MAH; Klein SL; Pekosz A; Permar S; Konnikova L; Yonker LM; Lauffenburger D; Nelson A; Elovitz MA; Edlow AG
    medRxiv; 2024 Jul; ():. PubMed ID: 39072025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Respiratory Syncytial Virus Maternal Vaccination in Infants below 6 Months of Age: Meta-Analysis of Safety, Immunogenicity, and Efficacy.
    Mapindra MP; Mahindra MP; McNamara P; Semple MG; Clark H; Madsen J
    Neonatology; 2024; 121(3):271-282. PubMed ID: 38286126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial.
    Kotb S; Haranaka M; Folschweiller N; Nakanwagi P; Verheust C; De Schrevel N; David MP; Mesaros N; Hulstrøm V
    Respir Investig; 2023 Mar; 61(2):261-269. PubMed ID: 36641341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults.
    Baber J; Arya M; Moodley Y; Jaques A; Jiang Q; Swanson KA; Cooper D; Maddur MS; Loschko J; Gurtman A; Jansen KU; Gruber WC; Dormitzer PR; Schmoele-Thoma B
    J Infect Dis; 2022 Dec; 226(12):2054-2063. PubMed ID: 35543281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are maternal vaccines effective and safe for mothers and infants? A systematic review and meta-analysis of randomised controlled trials.
    de Bruin O; Phijffer E; Ahmadizar F; van der Maas N; Wildenbeest J; Sturkenboom M; Bont L; Bloemenkamp K
    BMJ Glob Health; 2023 Oct; 8(10):. PubMed ID: 37899087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Level of maternal antibodies against respiratory syncytial virus (RSV) nucleoprotein at birth and risk of RSV very severe lower respiratory tract infection.
    Receveur M; Ottmann M; Reynes JM; Eleouet JF; Galloux M; Receveur A; Ploin D; Fiorini S; Rivat N; Valette M; Lina B; Casalegno JS
    Influenza Other Respir Viruses; 2023 Jan; 17(1):e13025. PubMed ID: 36251946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medically Attended Illness due to Respiratory Syncytial Virus Infection Among Infants Born in the United States Between 2016 and 2020.
    Gantenberg JR; van Aalst R; Zimmerman N; Limone B; Chaves SS; La Via WV; Nelson CB; Rizzo C; Savitz DA; Zullo AR
    J Infect Dis; 2022 Aug; 226(Suppl 2):S164-S174. PubMed ID: 35968869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group.
    Groothuis JR; Simoes EA; Hemming VG
    Pediatrics; 1995 Apr; 95(4):463-7. PubMed ID: 7700741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI).
    Straňák Z; Saliba E; Kosma P; Posfay-Barbe K; Yunis K; Farstad T; Unnebrink K; van Wyk J; Wegzyn C; Notario G; Kalus S; Campbell FJ
    PLoS One; 2016; 11(6):e0157446. PubMed ID: 27310438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hospitalisation of late preterm infants due to lower respiratory tract infections in Lithuania, Latvia, and Estonia: incidence, disease severity, and risk factors.
    Drazdienė N; Tamelienė R; Kviluna D; Saik P; Saik E; Zaikauskienė J
    Acta Med Litu; 2018; 25(2):76-85. PubMed ID: 30210241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical impact of multiple prevention strategies for respiratory syncytial virus infections in infants and high-risk toddlers in the United States.
    Ektare V; Lang J; Choi Y; Finelli L
    Vaccine; 2022 Oct; 40(42):6064-6073. PubMed ID: 36096968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial.
    Ruckwardt TJ; Morabito KM; Phung E; Crank MC; Costner PJ; Holman LA; Chang LA; Hickman SP; Berkowitz NM; Gordon IJ; Yamshchikov GV; Gaudinski MR; Lin B; Bailer R; Chen M; Ortega-Villa AM; Nguyen T; Kumar A; Schwartz RM; Kueltzo LA; Stein JA; Carlton K; Gall JG; Nason MC; Mascola JR; Chen G; Graham BS;
    Lancet Respir Med; 2021 Oct; 9(10):1111-1120. PubMed ID: 33864736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors and incidence of hospitalization due to respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in non-prophylaxed moderate-to-late preterm infants in Bosnia and Herzegovina.
    Maksić H; Heljić S; Skokić F; Šumanović-Glamuzina D; Milošević V; Zlatanović A; Gerard N
    Bosn J Basic Med Sci; 2018 Aug; 18(3):279-288. PubMed ID: 29750895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The long road to protect infants against severe RSV lower respiratory tract illness.
    Jares Baglivo S; Polack FP
    F1000Res; 2019; 8():. PubMed ID: 31105933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks' Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study.
    Papenburg J; Defoy I; Massé E; Caouette G; Lebel MH
    J Pediatric Infect Dis Soc; 2021 Apr; 10(3):237-244. PubMed ID: 32530035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.